MedPath

FDA Updates Pemgarda EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility Data

• The FDA updated the PEMGARDA™ EUA Fact Sheet to reflect accurate in vitro neutralization activity against dominant circulating variants KP.3.1.1 and LB.1. • The updated Fact Sheet removes a contested statement regarding potentially reduced susceptibility of KP.3.1.1 to pemivibart, based on data from LabCorp's Monogram Biosciences lab. • Invivyd continues active variant monitoring and asserts that PEMGARDA is likely to retain adequate neutralization activity against currently circulating SARS-CoV-2 variants in the U.S. • Invivyd emphasizes the importance of relying on validated, scientific studies conducted with authentic pemivibart for assessing neutralization potency and variant susceptibility.

Invivyd, Inc. (Nasdaq: IVVD) announced that the U.S. Food and Drug Administration (FDA) has re-issued an updated Emergency Use Authorization (EUA) Fact Sheet for PEMGARDA™ (pemivibart) to provide accurate in vitro neutralization activity data against dominant circulating SARS-CoV-2 variants, including KP.3.1.1 and LB.1. The updated Fact Sheet, dated September 26, 2024, addresses previous concerns regarding the susceptibility of the KP.3.1.1 variant to pemivibart.

Correction of Previous Data

The FDA's updated Fact Sheet removes a contested statement that indicated KP.3.1.1 may have substantially reduced susceptibility to pemivibart based on preliminary, non-peer-reviewed data. The revision incorporates viral neutralization data for pemivibart, aligning with prior variants represented in the CANOPY Phase 3 clinical trial. This data, generated by LabCorp’s Monogram Biosciences lab and provided to the FDA on September 3, 2024, supports the conclusion that PEMGARDA is likely to retain adequate neutralization activity against SARS-CoV-2 variants currently circulating in the U.S., including KP.3.1.1.

Importance of Validated Scientific Studies

Invivyd emphasizes the importance of relying on validated, scientific studies conducted with authentic pemivibart to assess neutralization potency and likely variant susceptibility. The company cautions against the use of neutralization findings of unknown quality that may be put into the public domain by various laboratories, some of which may have competing interests. According to Marc Elia, Chairman of the Invivyd Board of Directors, accurate and reliable industrial-grade applications of virology, using the actual pharmaceutical agent authorized for medical use, are central for healthcare professionals, patients, and other stakeholders to understand the risk-benefit profile of PEMGARDA.

PEMGARDA Overview

PEMGARDA™ (pemivibart) is a half-life extended investigational monoclonal antibody (mAb) engineered from adintrevimab. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), inhibiting virus attachment to the human ACE2 receptor on host cells. It is authorized for emergency use by the U.S. FDA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise and are unlikely to mount an adequate immune response to COVID-19 vaccination. PEMGARDA is not authorized for the treatment or post-exposure prophylaxis of COVID-19 and is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended.

Ongoing Variant Monitoring

Invivyd continues to actively monitor variants using validated methods and is not aware of any circulating variants not susceptible to PEMGARDA at this time. The company relies on extensive structural analysis and neutralization bioassays to assess variant susceptibility in partnership with the FDA, subject to the requirements in the PEMGARDA Letter of Authorization.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Monoclonal Antibody Shows Promise Against Dominant COVID-19 Variant

Inviyd's monoclonal antibody, pemivibart (Pemgarda), has demonstrated neutralizing activity against over 75% of currently circulating US COVID-19 variants and all prior tested variants, showcasing its potential in combating the virus's evolution.

Invivyd's Pemgarda Shows Continued Neutralizing Activity Against SARS-CoV-2 Variant XEC

Invivyd's PEMGARDA (pemivibart) demonstrates consistent neutralizing activity against the dominant SARS-CoV-2 variant XEC in new in vitro data.
XEC and KP.3.1.1, both susceptible to PEMGARDA, constitute the majority (69%) of circulating SARS-CoV-2 variants in the U.S., according to CDC estimates.

FDA Updates Fludarabine Labeling Under Project Renewal Initiative

The FDA has approved updated labeling for fludarabine phosphate injection under Project Renewal, an initiative focused on modernizing oncology drug labels.
The updated label provides clearer guidance for using fludarabine phosphate in combination with cyclophosphamide and rituximab for B-cell CLL treatment.

Invivyd's Pemivibart Shows Long-Term COVID-19 Protection in CANOPY Trial

Invivyd's CANOPY phase 3 trial data demonstrates pemivibart's efficacy as pre-exposure prophylaxis (PrEP) for COVID-19, including protection against recent JN.1 sublineages.
Pemivibart (Pemgarda) received EUA from the FDA for PrEP of COVID-19 in immunocompromised patients, supported by immunobridging data from the CANOPY trial.

FDA Approves PI3Kα Inhibitor/Degrader Alpelisib for Advanced Breast Cancer

The FDA has approved alpelisib, a PI3Kα inhibitor that also functions as a degrader, for treating advanced or metastatic breast cancer with PIK3CA mutations.
Alpelisib's dual mechanism offers a potential advantage by both inhibiting and degrading the PI3Kα protein, enhancing its therapeutic effect.

Invivyd's Pemivibart Shows 76% Protection Rate Against COVID-19 in Phase 3 Trial

Invivyd's Pemivibart demonstrated a 64% relative risk reduction in COVID-19 infection compared to placebo during months 7-12 of the CANOPY Phase 3 trial.
The trial showed an overall 12-month protection rate of 76% following two doses of Pemivibart, indicating sustained efficacy without continued dosing.

FDA Approves Labeling Change for Biktarvy Based on Clinical Data

The FDA has approved a labeling change for Biktarvy, an HIV-1 treatment, based on new clinical data.
This approval reflects ongoing updates to the drug's efficacy and safety profile as new data emerges.

Invivyd's Pemivibart Shows Promising Clinical Efficacy in COVID-19 Prevention

Invivyd's pemivibart, an investigational mAb, is being evaluated in the Phase 3 CANOPY trial for COVID-19 prevention in immunocompromised individuals and those at risk of exposure.
The CANOPY study assesses pemivibart's efficacy in preventing symptomatic COVID-19, with additional objectives including safety, tolerability, pharmacokinetics, and prevention of RT-PCR-confirmed cases.

FDA Updates Pemgarda EUA Due to Emerging SARS-CoV-2 Variants

The FDA has revised the Emergency Use Authorization for Pemgarda, limiting its use to situations where variants with reduced susceptibility are 90% or less of circulating strains.
This decision follows data indicating some SARS-CoV-2 variants, like KP.3.1.1, may exhibit substantially reduced susceptibility to Pemgarda.

FDA Approves Biktarvy Label Update With Data for Pregnant Adults with HIV

The FDA has approved an updated label for Biktarvy, including data supporting its safety and efficacy for treating pregnant individuals with HIV-1 who have suppressed viral loads. This update is based on Study 5310, which evaluated Biktarvy's pharmacokinetics, safety, and efficacy during pregnancy and postpartum.

Reference News

[1]
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate ...
biospace.com · Oct 1, 2024

FDA updates PEMGARDA Fact Sheet, removing contested statement on KP.3.1.1's reduced susceptibility to pemivibart. New da...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy